About FDA
Number of industry meetings attended within the month
Dictionary: Number of industry meetings held, including face-to-face meetings and meetings held over the telephone, within the month that OBP participated in. These meeting facilitate communication with industry to help ensure appropriate product development.
These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.
Fiscal Year - 2011
| Time | Target | Number |
|---|---|---|
| Oct 2010 | N/A | 23 |
| Nov 2010 | N/A | 25 |
| Dec 2010 | N/A | 23 |
| Jan 2011 | N/A | 23 |
| Feb 2011 | N/A | 27 |
| Mar 2011 | N/A | 33 |
| Apr 2011 | N/A | 35 |
| May 2011 | N/A | 27 |
| Jun 2011 | N/A | 36 |
| Jul 2011 | N/A | 26 |
| Aug 2011 | N/A | 34 |
| Sep 2011 | N/A | 17 |
FY 2011 Total: 329
Number of OBP-managed product quality meetings, held with industry within the month
Dictionary: Number of OBP-managed product quality meetings, including teleconferences and in-person meetings, held with industry within the month. These meeting facilitate communication with industry to help ensure appropriate product development. However they are focused on product quality, manufacturing and related safety issues.
Fiscal Year - 2011
| Time | Target | Number |
|---|---|---|
| Oct 2010 | N/A | 4 |
| Nov 2010 | N/A | 5 |
| Dec 2010 | N/A | 7 |
| Jan 2011 | N/A | 4 |
| Feb 2011 | N/A | 3 |
| Mar 2011 | N/A | 8 |
| Apr 2011 | N/A | 1 |
| May 2011 | N/A | 3 |
| Jun 2011 | N/A | 5 |
| Jul 2011 | N/A | 6 |
| Aug 2011 | N/A | 5 |
| Sep 2011 | N/A | 8 |
FY 2011 Total: 59
Glossary
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.
